Adult Acute Myeloblastic Leukemia Without Maturation (M1) Completed Phase 1 Trials for Cytarabine (DB00987)

IndicationStatusPhase
DBCOND0028523 (Adult Acute Myeloblastic Leukemia Without Maturation (M1))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01031368Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid LeukemiaTreatment
NCT01555268Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaTreatment
NCT00098423Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesTreatment
NCT00357305Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersTreatment
NCT00470197Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute LeukemiaTreatment
NCT01127009Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaTreatment